Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk

Anti-CD19 chimeric antigen receptor T (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, when high tumor bulk occurs, patients tend to early progression after CAR-T therapy. Here, we investigated whether pretreatment with inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Cuicui, Cui, Rui, Wang, Jia, Mou, Nan, Jiang, Yanyu, Li, Wei, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361834/
https://www.ncbi.nlm.nih.gov/pubmed/34395279
http://dx.doi.org/10.3389/fonc.2021.706087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361834/
https://www.ncbi.nlm.nih.gov/pubmed/34395279
http://dx.doi.org/10.3389/fonc.2021.706087

Ejemplares similares